Lesinurad is a novel URAT1 inhibitor developed by Ardea Biosciences, now a subsidiary of AstraZeneca, and was approved by the U.S. Food and Drug Administration (FDA) in 2015 and by the European Medicines Agency (EMA) in 2016 for the treatment of hyperuricemia associated with gout in combination with an XOI. This evidence concerns the gene SLC22A12 and gout.